Vita Life Sciences (VLS) H2 2025 earnings summary

Executive summary

• Achieved record revenue of $93.3 million, up 17% year-over-year, with broad-based growth across core markets and channels.

• Net profit after tax rose 18.8% to $10.4 million, and profit before tax increased 14.1% to $14.4 million compared to FY2024.

• Maintained a debt-free position and increased net assets to $56.2 million, up 7.4% year-over-year.

• Declared total dividends of 14.0 cents per share, a 40% increase, marking the 16th consecutive year of dividend payments.

• Continued investment in brand development, marketing, and operational capability to support long-term growth.

Financial highlights

• Sales revenue: $93.3 million, up 17.3% year-over-year.

• Net cash balance: $35.6 million, up 24.3% year-over-year.

• Net profit after tax: $10.4 million, up 18.8% year-over-year.

• Earnings per share: 18.6 cents, up 18.0% year-over-year.

• Total equity: $56.2 million, up 7.4% year-over-year.

• Operating cash flow before interest and tax: $18.8 million.

Outlook and guidance

• Entering 2026 with strong momentum and a clear strategic focus on capturing long-term health and wellness trends.

• Plans to increase investment in advertising, promotion, and distribution channel expansion, which may impact short-term profitability but aims to drive medium-term growth.

• Confident in ability to deliver sustainable growth and long-term shareholder value.